E
Elizabeth Molsen
Publications - 9
Citations - 2464
Elizabeth Molsen is an academic researcher. The author has contributed to research in topics: Outcomes research & European union. The author has an hindex of 8, co-authored 8 publications receiving 1847 citations.
Papers
More filters
Journal ArticleDOI
Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.
Donald L. Patrick,Laurie B. Burke,Chad J. Gwaltney,Nancy Kline Leidy,Mona L. Martin,Elizabeth Molsen,Lena Ring +6 more
TL;DR: This task force report is intended to offer suggestions for good practice in planning, executing, and documenting qualitative studies that are used to support the content validity of PRO instruments to be used in medical product evaluation.
Journal ArticleDOI
Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO Instrument
Donald L. Patrick,Laurie B. Burke,Chad J. Gwaltney,Nancy Kline Leidy,Mona L. Martin,Elizabeth Molsen,Lena Ring +6 more
TL;DR: Suggestions for good practices in planning, executing, and documenting qualitative studies that are used to support the content validity of PRO instruments to be used in medical product evaluation are offered.
Journal ArticleDOI
Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group.
Trevor Richter,Sandra Nestler-Parr,Robert Babela,Zeba M. Khan,Theresa Tesoro,Elizabeth Molsen,Dyfrig A. Hughes +6 more
TL;DR: Despite variation in the terminology and prevalence thresholds used to define rare diseases among different jurisdictions and organizations, the terms "rare disease" and "orphan drug" are used most widely and the average prevalence threshold is between 40 and 50 cases/100,000 people.
Journal ArticleDOI
Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report.
D Wild,Sonya Eremenco,Isabelle Mear,Mona L. Martin,Caroline Houchin,M.C. Gawlicki,Asha Hareendran,Ingela Wiklund,Lee Yee Chong,Robyn von Maltzahn,Lawrence Cohen,Elizabeth Molsen +11 more
TL;DR: This report and the decision tools proposed will assist those involved with multinational trials to decide on the translations required for each country and choose the approach to use when the same language is spoken in more than one country.
Journal ArticleDOI
Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force
Marc K. Walton,John H. Powers,Jeremy Hobart,Donald L. Patrick,Patrick Marquis,Sprios Vamvakas,Maria Isaac,Elizabeth Molsen,Stefan J. Cano,Laurie B. Burke +9 more
TL;DR: The foundation provided in this report includes what it means to demonstrate a beneficial effect, how assessments of patients relate to the objective of showing a treatment's benefit, and how these assessments are used in clinical trial endpoints.